Tanya Bardakjian

Tanya Bardakjian

Auto-generated profile, based on publicly available information

Tanya Bardakjian

Department of Neurology Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2021 in Journal of Genetic Counseling
Verified
Journal Article
Open access
PDF file
LDLaynie Dratch
Laynie Dratch
RPRachel A. Paul
Rachel A. Paul
ABAaron Baldwin
Aaron Baldwin
MBMorgan Brzozowski
Morgan Brzozowski
PGPedro Gonzalez‐Alegre
Pedro Gonzalez‐Alegre
TBTanya Bardakjian
Tanya Bardakjian
The COVID‐19 pandemic rapidly changed genetic counseling services across the United States. At the University of Pennsylvania (UPenn), a large academic hospital in an urban setting, nearly all genetic counseling (GC) visits for adult–onset disorders within the Department of Neurology were conducted via secure videoconferencing (telegenetics) or telephone between March and December 2020. Although telemedicine services have been steadily emerging, many clinical programs, including the neurogenetics program at UPenn, had not built infrastructure or widely utilized these services prior to the pandemic. Thus, little is known about patient attitudes toward receiving clinical GC services remotely. From May 18 to October 18, 2020, all individuals seen remotely for GC in adult neurology via telephone or telegenetics were surveyed about their satisfaction with telehealth GC (N = 142), with a response rate of 42% (N = 60/142). Telephone and telegenetics services were referred to as ‘telehealth’ in the surveys to capture patient perspectives on all remote GC services, though the majority (N = 49/60) of these visits were completed via telegenetics. Surveys included the modified telehealth usability questionnaire (MTUQ), genetic counseling satisfaction scale (GCSS), and novel questions about future telehealth use. Preliminary results suggest that patients were satisfied with receiving remote GC services in adult neurology, with most participants strongly agreeing to all items about satisfaction with telehealth. Just 2% of participants preferred only in‐person visits in the future, but every participant was willing to consider using telehealth for future visits if their genetic counselor felt it was appropriate. Most participants preferred a hybrid model (73%), and some (25%) preferred only telehealth for future visits. Additionally, we found no differences in satisfaction with remote services based on visit type (initial vs. results disclosure) nor age. We conclude that remote GC is an acceptable method for the provision of services in adult neurology that is well‐received by patients.

Verified
Journal Article
Open access
PDF file
CHCheng-Tsung Hsiao
Cheng-Tsung Hsiao
TTThomas Tropea
Thomas Tropea
SFSsu-Ju Fu
Ssu-Ju Fu
TBTanya M. Bardakjian
Tanya M. Bardakjian
PGPedro Gonzalez-Alegre
Pedro Gonzalez-Alegre
CJChung-Jiuan Jeng
Chung-Jiuan Jeng
Loss-of-function mutations in the KV4.3 channel-encoding KCND3 gene are linked to neurodegenerative cerebellar ataxia. Patients suffering from neurodegeneration associated with iron deposition may also present with cerebellar ataxia. The mechanism underlying brain iron accumulation remains unclear. Here, we aim to ascertain the potential pathogenic role of KCND3 variant in iron accumulation-related cerebellar ataxia. We presented a patient with slowly progressive cerebellar ataxia, parkinsonism, cognitive impairment, and iron accumulation in the basal ganglia and the cerebellum. Whole exome sequencing analyses identified in the patient a heterozygous KCND3 c.1256G>A (p.R419H) variant predicted to be disease-causing by multiple bioinformatic analyses. In vitro biochemical and immunofluorescence examinations revealed that, compared to the human KV4.3 wild-type channel, the p.R419H variant exhibited normal protein abundance and subcellular localization pattern. Electrophysiological investigation, however, demonstrated that the KV4.3 p.R419H variant was associated with a dominant increase in potassium current amplitudes, as well as notable changes in voltage-dependent gating properties leading to enhanced potassium window current. These observations indicate that, in direct contrast with the loss-of-function KCND3 mutations previously reported in cerebellar ataxia patients, we identified a rare gain-of-function KCND3 variant that may expand the clinical and molecular spectra of neurodegenerative cerebellar disorders associated with brain iron accumulation.

25 September 2021 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
PDF file
LALouise Amlie‐Wolf
Louise Amlie‐Wolf
TBTanya Bardakjian
Tanya Bardakjian
SKSarina M. Kopinsky
Sarina M. Kopinsky
LRLinda Reis
Linda Reis
ESElena Semina
Elena Semina
ASAdele Schneider
Adele Schneider
SOX2 variants and deletions are a common cause of anophthalmia and microphthalmia (A/M). This article presents data from a cohort of patients with SOX2 variants, some of whom have been followed for 20+ years. Medical records from patients enrolled in the A/M Research Registry and carrying SOX2 variants were reviewed. Thirty‐seven patients were identified, ranging in age from infant to 30 years old. Eye anomalies were bilateral in 30 patients (81.1%), unilateral in 5 (13.5%), and absent in 2 (5.4%). Intellectual disability was present in all with data available and ranged from mild to profound. Seizures were noted in 18 of 27 (66.6%) patients, usually with abnormal brain MRIs (10/15, 66.7%). Growth issues were reported in 14 of 21 patients (66.7%) and 14 of 19 (73.7%) had gonadotropin deficiency. Genitourinary anomalies were seen in 15 of 19 (78.9%) male patients and 5 of 15 (33.3%) female patients. Patients with SOX2 nucleotide variants, whole gene deletions or translocations are typically affected with bilateral or unilateral microphthalmia and anophthalmia. Other associated features include intellectual disability, seizures, brain anomalies, growth hormone deficiency, gonadotropin deficiency, and genitourinary anomalies. Recommendations for newly diagnosed patients with SOX2 variants include eye exams, MRI of the brain and orbits, endocrine and neurology examinations. Since the clinical spectrum associated with SOX2 alleles has expanded beyond the originally reported phenotypes, we propose a broader term, SOX2‐associated disorder, for this condition.

1 August 2018 in Journal of American Association for Pediatric Ophthalmology and Strabismus
Verified
Journal Article
Closed access
MPMaria Pefkianaki
Maria Pefkianaki
ASAdele Schneider
Adele Schneider
JCJenina E. Capasso
Jenina E. Capasso
BWBarry N. Wasserman
Barry N. Wasserman
TBTanya Bardakjian
Tanya Bardakjian
ALAlex V. Levin
Alex V. Levin

21 December 2018 in Neuromuscular Disorders
Verified
Journal Article
Closed access
LDLois Dankwa
Lois Dankwa
JRJessica Richardson
Jessica Richardson
WMWilliam W. Motley
William W. Motley
MSMena Scavina
Mena Scavina
SCSteve Courel
Steve Courel
SSSteven S. Scherer
Steven S. Scherer

23 May 2025 in Journal of Genetic Counseling
Verified
Journal Article
Open access
RPRachel A. Paul
Rachel A. Paul
NBNareen Babaian
Nareen Babaian
MBMorgan Brzozowski
Morgan Brzozowski
ABAaron Baldwin
Aaron Baldwin
KJKelsey Johnson
Kelsey Johnson
LDLaynie Dratch
Laynie Dratch
At our center, we offer clinical genetic counseling (GC) visits for adults with a personal and/or family history of neurologic disease. Here, we report patient experience and outcomes from different visit modalities (e.g., in person, videoconferencing, and telephone) in clinical neurogenetics. Individuals who completed a GC visit in the Neurology Department at the University of Pennsylvania between January 2021 and January 2023 were surveyed after an initial evaluation and/or a disclosure visit. Questionnaires included items validated to measure satisfaction with GC, satisfaction with telehealth, and patient empowerment. Two hundred and ninety‐nine individuals submitted 347 survey responses, representing a response rate of 42% (initial) and 31% (disclosure) for each of the surveys. Most responders completed their initial visit in person, while most completed their disclosure visit remotely via videoconferencing or telephone. Patient satisfaction with GC did not differ between visit modalities. For initial visits, telehealth satisfaction was higher for visits regarding the consideration of predictive testing compared to diagnostic testing. For follow‐up visits, telehealth satisfaction was higher for videoconferencing compared to telephone disclosure. A majority of responders (69%–78%) reported interest in utilizing telehealth in the future if their genetic counselor thought it was appropriate and a majority of responders (65%–79%) indicated a preference for a combination of in‐person and telehealth visits. Individuals who completed an initial visit in person were more likely to decline interest in future telehealth use. This study allowed for some comparison between visit modalities, but more research is needed to understand individuals' preferences and guide recommendations for GC service delivery.